NT-proBNP/urine hepcidin-25 ratio and cardiorenal syndrome type 1 in patients with severe symptomatic aortic stenosis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52(19), 1527–1539 (2008).
  MedlineGoogle Scholar
• 2. Witberg G, Steinmetz T, Landes U et al. Change in kidney function and 2-year mortality after transcatheter aortic valve replacement. JAMA Netw. Open 4(3), e213296 (2021).
  MedlineGoogle Scholar
• 3. Patel KK, Shah SY, Arrigain S et al. Characteristics and outcomes of patients with aortic stenosis and chronic kidney disease. J. Am. Heart Assoc. 8(3), e009980 (2019).
  MedlineGoogle Scholar
• 4. Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J. Am. Coll. Cardiol. 60(12), 1031–1042 (2012). • Review exploring the pathophysiological pathways of cardiorenal syndrome type 1, including common pathways of bidirectional organ injury.
  MedlineGoogle Scholar
• 5. Haase M, Müller C, Damman K et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib. Nephrol. 182, 99–116 (2013).
  MedlineGoogle Scholar
• 6. Uduman J. Epidemiology of cardiorenal syndrome. Adv. Chronic Kidney Dis. 25(5), 391–399 (2018).
  MedlineGoogle Scholar
• 7. Eren Z, Ozveren O, Buvukoner E, Kaspar E, Degertekin M, Kantarci G. A single-centre study of acute cardiorenal syndrome: incidence, risk factors and consequences. Cardiorenal. Med. 2(3), 168–176 (2012).
  MedlineGoogle Scholar
• 8. Adachi Y, Yamamoto M. OCEAN-SHD family. Chronic kidney disease and transcatheter aortic valve implantation. Cardiovasc. Interv. Ther. 37(3), 458–464 (2022).
  MedlineGoogle Scholar
• 9. Gembillo G, Visconti L, Giusti MA et al. Cardiorenal syndrome: new pathways and novel biomarkers. Biomolecules 11(11), 1581 (2021).
  Medline CASGoogle Scholar
• 10. Cui H, Huo G, Liu L et al. Association of cardiac and renal function with extreme N-terminal fragment pro-B-type natriuretic peptide levels in elderly patients. BMC Cardiovasc. Disord. 12, 57 (2012). •• This retrospective study analyzed the value of extreme elevation of NTpro-BNP levels in 152 elderly patients.
  Medline CASGoogle Scholar
• 11. Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int. Suppl. 11(1), 46–58 (2021).
  Google Scholar
• 12. van Swelm RP, Wetzels JF, Verweij VG et al. Renal handling of circulating and renal-synthesized hepcidin and its protective effects against hemoglobin-mediated kidney injury. J. Am. Soc. Nephrol. 27(9), 2720–2732 (2016).
  Medline CASGoogle Scholar
• 13. Min HK, Oh YK, Choi KH et al. Relationship between cardiac geometry and serum hepcidin in chronic kidney disease: analysis from the KNOW-CKD Study. J. Korean Med. Sci. 35(1), e2 (2020).
  Medline CASGoogle Scholar
• 14. Haase-Fielitz A, Mertens PR, Plass M et al. Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study. Crit. Care 15(4), R186 (2011). •• This prospective cohort study evaluated the value of urine hepcidin as an early predictive biomarker of ruling out acute kidney injury after cardiopulmonary bypass.
  MedlineGoogle Scholar
• 15. Haase-Fielitz A, Plaß M, Kuppe H et al. Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: a pilot study. J. Thorac. Cardiovasc. Surg. 145(5), 1380–1386 (2013).
  Medline CASGoogle Scholar
• 16. Choi N, Rigatto C, Zappitelli M et al. Urinary hepcidin-25 is elevated in patients that avoid acute kidney injury following cardiac surgery. Can. J. Kidney Health Dis. 5, 2054358117744224 (2018).
  Google Scholar
• 17. Ganz T, Nemeth E. Iron balance, and the role of hepcidin in chronic kidney disease. Semin. Nephrol. 36(2), 87–93 (2016).
  Medline CASGoogle Scholar
• 18. Paragas N, Qiu A, Zhang Q et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat. Med. 17(2), 216–222 (2011).
  Medline CASGoogle Scholar
• 19. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365(9466), 1231–1238 (2005).
  Medline CASGoogle Scholar
• 20. Haase M, Bellomo R, Devarajan P et al. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 54(6), 1012–1024 (2009).
  Medline CASGoogle Scholar
• 21. Vasques-Nóvoa F, Pedro Ferreira J, Marques P et al. Interleukin-6, infection, and cardiovascular outcomes in acute heart failure: findings from the EDIFICA registry. Cytokine 160, 156053 (2022).
  Medline CASGoogle Scholar
• 22. McGeough MD, Pena CA, Mueller JL et al. Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models. J. Immunol. 189(6), 2707–2711 (2012).
  Medline CASGoogle Scholar
• 23. McCullough PA, Bouchard J, Waikar SS et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 182, 5–12 (2013).
  MedlineGoogle Scholar
• 24. Vahanian A, Beyersdorf F, Praz F et al. ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev. Esp. Cardiol. (Engl. Ed.) 75(6), 524 (2022).
  MedlineGoogle Scholar
• 25. Chang KW, Hsu JC, Toomu A, Fox S, Maisel AS. Clinical applications of biomarkers in atrial fibrillation. Am. J. Med. 130, 1351–1355 (2017).
  Medline CASGoogle Scholar
• 26. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur. Heart J. 33(19), 2403–2418 (2012).
  MedlineGoogle Scholar
• 27. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315(8), 801–810 (2016).
  Medline CASGoogle Scholar
• 28. Levey AS, Stevens LA, Schmid CH et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009).
  MedlineGoogle Scholar
• 29. Nashef SA, Roques F, Sharples LD et al. EuroSCORE II. Eur. J. Cardiothorac. Surg. 41, 734–744 (2012).
  MedlineGoogle Scholar
• 30. Cubeddu RJ, Asher CR, Lowry AM et al. PARTNER Trial Investigators. Impact of transcatheter aortic valve replacement on severity of chronic kidney disease. J. Am. Coll. Cardiol. 76(12), 1410–1421 (2020).
  MedlineGoogle Scholar
• 31. Lemes da Silva MV, Nunes Filho ACB, Rosa VEE et al. Improvement of renal function after transcatheter aortic valve replacement in patients with chronic kidney disease. PLOS ONE 16(5), e0251066 (2021).
  MedlineGoogle Scholar
• 32. Jäckel M, Keller S, Prager EP et al. The impact of transcatheter aortic valve implantation planning and procedure on acute and chronic renal failure. Cardiol. J. 30(2), 247–255 (2021).
  MedlineGoogle Scholar
• 33. Haase-Fielitz A, Altendeitering F, Iwers R et al. Acute kidney injury may impede results after transcatheter aortic valve implantation. Clin. Kidney J. 14(1), 261–268 (2020).
  MedlineGoogle Scholar
• 34. Kato A. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome. Future Cardiol. 6(6), 769–771 (2010).
  CASGoogle Scholar
• 35. Kulaksiz H, Theilig F, Bachmann S et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J. Endocrinol. 184, 361–370 (2005).
  Medline CASGoogle Scholar
• 36. Prowle JR, Ostland V, Calzavacca P et al. Greater increase in urinary hepcidin predicts protection from acute kidney injury after cardiopulmonary bypass. Nephrol. Dial. Transplant. 27, 595–602 (2012).
  Medline CASGoogle Scholar
• 37. Ho J, Reslerova M, Gali B et al. Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin. J. Am. Soc. Nephrol. 6(10), 2340–2346 (2011).
  Medline CASGoogle Scholar